Acrivon Therapeutics, Inc. Quarterly Earnings Per Share, Basic in USD/shares from Q3 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD/shares
Description
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Summary
Acrivon Therapeutics, Inc. quarterly/annual Earnings Per Share, Basic history and growth rate from Q3 2021 to Q3 2024.
  • Acrivon Therapeutics, Inc. Earnings Per Share, Basic for the quarter ending September 30, 2024 was -0.59 USD/shares, a 10.6% increase year-over-year.
  • Acrivon Therapeutics, Inc. Earnings Per Share, Basic for the twelve months ending September 30, 2024 was -2.71 USD/shares, a 187% decline year-over-year.
  • Acrivon Therapeutics, Inc. annual Earnings Per Share, Basic for 2023 was -2.74 USD/shares, a 63.8% increase from 2022.
  • Acrivon Therapeutics, Inc. annual Earnings Per Share, Basic for 2022 was -7.56 USD/shares, a 18.9% increase from 2021.
Earnings Per Share, Basic, Trailing 12 Months (USD/shares)
Earnings Per Share, Basic, Quarterly (USD/shares)
Earnings Per Share, Basic, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$3 -$1 +$0.07 +10.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$3 -$1 +$0.11 +17.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$3 -$1 $0 -25.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$3 -$1 -$6 -117% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 $3.11 -$1 +$4.51 +87.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$1 -$1 +$2.66 +80.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$4 -$1 +$3.50 +85.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$8 $4.98 Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$5 -$4 -275% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$3 Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 -$4 Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q3 2021 -$1 Jul 1, 2021 Sep 30, 2021 10-Q 2022-12-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.